WO2022146096A1 - Souche de lactobacillus sp., souche de bifidobacterium sp. ou souche de ruminococcus sp., vésicules dérivées de celles-ci et utilisations anti-inflammatoires et antibactériennes associées - Google Patents

Souche de lactobacillus sp., souche de bifidobacterium sp. ou souche de ruminococcus sp., vésicules dérivées de celles-ci et utilisations anti-inflammatoires et antibactériennes associées Download PDF

Info

Publication number
WO2022146096A1
WO2022146096A1 PCT/KR2021/020338 KR2021020338W WO2022146096A1 WO 2022146096 A1 WO2022146096 A1 WO 2022146096A1 KR 2021020338 W KR2021020338 W KR 2021020338W WO 2022146096 A1 WO2022146096 A1 WO 2022146096A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
endoplasmic reticulum
lactobacillus
lysate
culture medium
Prior art date
Application number
PCT/KR2021/020338
Other languages
English (en)
Korean (ko)
Inventor
김정현
강기성
Original Assignee
주식회사 바이오뱅크힐링
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200189815A external-priority patent/KR102269961B1/ko
Priority claimed from KR1020200189821A external-priority patent/KR102269965B1/ko
Priority claimed from KR1020200189818A external-priority patent/KR102296288B1/ko
Priority claimed from KR1020200189819A external-priority patent/KR102296289B1/ko
Priority claimed from KR1020200189820A external-priority patent/KR102296290B1/ko
Priority claimed from KR1020210004194A external-priority patent/KR102269966B1/ko
Application filed by 주식회사 바이오뱅크힐링 filed Critical 주식회사 바이오뱅크힐링
Publication of WO2022146096A1 publication Critical patent/WO2022146096A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • Microbiome refers to microorganisms that exist in a specific environment and their entire genetic information, and refers to a collection of genomes that refer to the entire genetic information of a single organism. Therefore, the human microbiome refers to microorganisms living inside and outside the human body and their entire genetic information.
  • the human body lives in a symbiotic relationship with many microorganisms, and in particular, the intestine contains the most microorganisms as an optimal environment for the microorganisms to take in nutrients and form a systematic community.
  • Intestinal microbes supply nutrients that cannot be produced by the host’s enzymes alone and are closely related to the host’s metabolism and immune system, while helping to prevent various diseases such as irritable bowel syndrome, obesity, atopy, depression, rheumatoid arthritis, autism spectrum disorder, and dementia. It has been reported to be associated with
  • the endoplasmic reticulum is a nano-sized material of about 20 to 200 nm produced and discharged by cells, and it is free to move between cells.
  • the endoplasmic reticulum contains membrane lipids, membrane proteins, DNA or RNA, and the like, and these genetic materials act as a complex to deliver toxic factors between cells and regulate inflammation and immune response. From unicellular organisms to multicellular organisms, information exchange between cells is an essential process of life phenomena, and recently, the endoplasmic reticulum has been recognized as a medium for information exchange between cells, so methods for using the vesicle as a drug carrier have been developed.
  • accession number KCTC 14400BP belonging to the genus Lactobacillus ( Lactobacillus sp. ) Lactobacillus sakei ( Lactobacillus sakei ) strain, deposited with accession number KCTC 14299BP, lactobacillus belonging to the genus ( Lactobacillus sp. ) Bacillus reuteri ( Lactobacillus reuteri ) strain, deposited with accession number KCTC 14298BP, belonging to the Lactobacillus genus ( Lactobacillus sp.
  • Lactobacillus gasseri Lactobacillus gasseri
  • Lactobacillus gasseri strain, deposited with accession number KCTC 14358BP, Bifidobacterium genus ( Bifidobacterium sp. ) Belonging to Bifidobacterium adolescentis ( Bifidobacterium adolescentis ) Strain, deposited with accession number KCTC 14405BP, Lactobacillus genus ( Lactobacillus sp.
  • Lactobacillus paragasseri Lactobacillus paragasseri
  • accession number It is to provide a strain of Ruminococcus faecis belonging to the genus Ruminococcus sp. , deposited as KCTC 14415BP.
  • Another aspect is to provide an endoplasmic reticulum derived from the strain, a lysate of the strain, or a culture solution.
  • Another aspect is to provide a pharmaceutical composition for preventing or treating inflammatory diseases comprising the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof as an active ingredient.
  • Another aspect is to provide a health functional food for the prevention or improvement of inflammatory diseases comprising the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof as an active ingredient.
  • Another aspect is to provide a health functional food for improving intestinal health comprising the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof as an active ingredient.
  • Another aspect is to provide a pharmaceutical composition for preventing or treating a bacterial infection comprising the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof as an active ingredient.
  • Another aspect is to provide a health functional food for preventing or improving bacterial infection comprising the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof as an active ingredient.
  • Another aspect is to provide a cosmetic composition
  • a cosmetic composition comprising the strain, the endoplasmic reticulum derived from the strain, a lysate of the strain, a culture solution, or a mixture thereof.
  • Another aspect is to provide an antibacterial composition for external application for skin comprising the strain, the endoplasmic reticulum derived from the strain, a lysate of the strain, a culture solution, or a mixture thereof.
  • Another aspect is to provide a method for preventing or treating an inflammatory disease by administering the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof to an individual in need thereof.
  • Another aspect is to provide a method for preventing or treating a bacterial infection by administering the strain, the endoplasmic reticulum derived from the strain, a lysate of the strain, a culture medium, or a mixture thereof to an individual in need thereof.
  • Another aspect is to provide use of the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof for the preparation of a composition for preventing or treating inflammatory diseases.
  • Another aspect is to provide the use of the strain, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or a mixture thereof for the preparation of a composition for preventing or treating bacterial infection.
  • accession number KCTC 14400BP belonging to the genus Lactobacillus ( Lactobacillus sp. ) Lactobacillus sakei ( Lactobacillus sakei ) strain, deposited with accession number KCTC 14299BP, lactobacillus belonging to the genus ( Lactobacillus sp. ) Bacillus reuteri ( Lactobacillus reuteri ) strain, deposited with accession number KCTC 14298BP, belonging to the Lactobacillus genus ( Lactobacillus sp.
  • Lactobacillus gasseri Lactobacillus gasseri
  • Lactobacillus gasseri strain, deposited with accession number KCTC 14358BP, Bifidobacterium genus ( Bifidobacterium sp. ) Belonging to Bifidobacterium adolescentis ( Bifidobacterium adolescentis ) Strain, deposited with accession number KCTC 14405BP, Lactobacillus genus ( Lactobacillus sp.
  • Lactobacillus paragasseri Lactobacillus paragasseri
  • accession number It provides a Ruminococcus faecis strain, which belongs to the Ruminococcus sp. , deposited as KCTC 14415BP.
  • the Lactobacillus Sakei strain may be a strain comprising 16S rRNA of SEQ ID NO: 1.
  • the Lactobacillus reuteri strain may be a strain comprising 16S rRNA of SEQ ID NO: 2.
  • the Lactobacillus gasseri strain may be a strain comprising 16S rRNA of SEQ ID NO: 3.
  • the Bifidobacterium adolecentis strain may be a strain comprising 16S rRNA of SEQ ID NO: 4.
  • the Lactobacillus paragasseri strain may be a strain comprising 16S rRNA of SEQ ID NO: 5.
  • the Luminococcus phaesis strain may be a strain comprising 16S rRNA of SEQ ID NO: 6.
  • the strain may have anti-inflammatory and/or antibacterial activity.
  • the strain inhibits the production of nitric oxide in the inflamed cells, inhibits the expression of inflammatory cytokines (eg, TNF- ⁇ or IL-6), or inhibits the proliferation of bacteria (eg, C. difficile ) may be inhibiting
  • the strain reduces inflammatory factors induced by C. difficile, for example, pro-inflammatory cytokines (eg, TNF, or CCL2), or increases anti-inflammatory cytokines (IL-10).
  • Another aspect is the endoplasmic reticulum derived from the Lactobacillus sack, Lactobacillus reuteri, Lactobacillus gasseri, Bifidobacterium adolecentis, Lactobacillus paragaseri or Luminococcus phaesis strain, lysate of the strain, culture medium, culture medium extracts, or mixtures thereof.
  • the strain is as described above.
  • vesicle refers to a particle secreted from a cell and released into the extracellular space, and includes an exosome, an ectosome, a microvesicle, and a microparticle. , exosome-like vesicles, and the like.
  • the extracellular ER can reflect the state of the secreting cell of origin (donor cell), exhibit various biological activities depending on which cell it is secreted from, and play an important role in cell-to-cell interactions by transferring genetic material and proteins between cells can do.
  • the cell-derived substances including the endoplasmic reticulum cause disease or stimulate immune cells to fight disease, and have the effect of helping to break down and absorb substances that humans cannot digest through the metabolic process of microorganisms.
  • the endoplasmic reticulum is a membrane-structured endoplasmic reticulum, which is divided into an inside and an outside, and has a plasma membrane lipid, a plasma membrane protein, a nucleic acid, and a cytoplasmic component of the cell, and is larger than the original cell. may be small.
  • the endoplasmic reticulum is from the cell lysate of the Lactobacillus sacki, Lactobacillus reuteri, Lactobacillus gasseri, Bifidobacterium adolecentis, Lactobacillus paragaseri or Luminococcus faecis strains. may be separate.
  • the extracellular vesicles may have a diameter of 10 nm to 400 nm.
  • it may be 10 nm to 400 nm, 10 nm to 350 nm, 10 nm to 300 nm, or 10 nm to 250 nm.
  • the term "culture medium” may be used interchangeably with “culture supernatant”, “conditioned culture medium” or “conditioned medium”, and to a medium capable of supplying nutrients so that the strain can grow and survive in vitro. It may mean the entire medium including the strain obtained by culturing the strain for a certain period, its metabolites, extra nutrients, and the like.
  • the culture solution may refer to a culture solution obtained by culturing the strain in which the cells are removed from the culture solution.
  • the liquid from which the cells have been removed from the culture medium is also called a "supernatant", and the culture solution is left for a certain period of time to take only the liquid from the upper layer except for the part that has sunk to the bottom layer, remove the cells through filtration, or centrifuge the culture solution to the lower part It can be obtained by removing the precipitation of and taking only the liquid at the top.
  • the "cell” of the present invention refers to the strain itself of the present invention, and includes the strain isolated and selected from a skin sample, or the strain isolated from the culture solution by culturing the strain. The cells can be obtained by centrifuging the culture medium and taking the part that has sunk to the lower layer, or by removing the liquid from the upper layer after leaving it still for a certain period of time because it sinks to the lower layer of the culture solution by gravity.
  • the culture medium may include the culture medium itself obtained by culturing the strain, its concentrate, or a lyophilisate or a culture supernatant obtained by removing the strain from the culture medium, its concentrate or lyophilisate.
  • the culture medium is Lactobacillus saccharis, Lactobacillus reuteri, Lactobacillus gasseri, Bifidobacterium adolecentis, Lactobacillus paragaseri or Luminococcus faecis in an appropriate medium (e.g., R2A medium or TSA medium). It may be obtained by culturing for a certain time, for example, 4 to 50 hours at any temperature of more than 10 °C or less than 40 °C.
  • an appropriate medium e.g., R2A medium or TSA medium
  • the culture supernatant of the strain may be obtained by centrifuging or filtering the strain culture to remove the strain.
  • the concentrate may be obtained by concentrating the supernatant obtained after filtering the strain culture solution itself, or the culture solution using centrifugation or a filter.
  • Lactobacillus Sake, Lactobacillus reuteri, Lactobacillus gasseri, Bifidobacterium adolecentis, Lactobacillus paragaseri or Luminococcus faecis culture medium and culture conditions for culturing the culturing conditions are those of ordinary skill in the art. You can use it by selecting or modifying it appropriately.
  • lysate may refer to a product obtained by crushing the cell wall of the strain itself by chemical or physical force.
  • culture solution extract means extraction from the culture solution or its concentrate, and may include an extract, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or these prepared or purified products, and a fraction obtained by fractionation thereof.
  • Lactobacillus Sake Lactobacillus reuteri, Lactobacillus gasseri, Bifidobacterium adolecentis, Lactobacillus paragaseri or Luminococcus phaesis strain, endoplasmic reticulum derived from the strain, disruption of the strain
  • a solution a culture solution, or an extract of the culture solution.
  • the term “treat” may mean that inflammation or bacterial infection is cured in a shorter time compared to natural healing.
  • the treatment may include amelioration and/or alleviation of inflammation or bacterial infection.
  • the treatment may refer to healing and/or recovery of symptoms caused by inflammation or bacterial infection.
  • the use of the strain may include preventing, ameliorating, or treating an inflammatory disease (anti-inflammatory activity), preventing, ameliorating, or treating a bacterial infection (antibacterial activity), or preventing or improving intestinal health.
  • an inflammatory disease anti-inflammatory activity
  • preventing, ameliorating, or treating a bacterial infection antibacterial activity
  • preventing or improving intestinal health may include preventing, ameliorating, or treating an inflammatory disease (anti-inflammatory activity), preventing, ameliorating, or treating a bacterial infection (antibacterial activity), or preventing or improving intestinal health.
  • the inflammatory disease may include inflammation of the digestive system (gastrointestinal tract, etc.), intraocular inflammation, oral inflammation, respiratory system inflammation including lung, skin inflammation, cardiovascular inflammation, brain inflammation, and ear inflammation. have.
  • the inflammatory disease is inflammatory bowel disease (IBD); irritable bowel syndrome; Behcet's disease; enteritis, Crohn's disease; ulcerative colitis; vasculitis; mucositis; stomatitis; peri-implantitis; periodontitis; pulpitis; gingivitis; Pneumonia; dermatitis; atopic dermatitis; contact dermatitis; CREST syndrome; dermatitis herpetiformis; dermatomyositis; systemic scleroderma; erythema nodosum; Henoch-Schonlein purpura; Hidradenitis suppurativa; lichen planus; Majeed syndrome; Schnitzler syndrome; psoriasis; eczema; acne; mouth ulcers; uveitis; pharyngitis; tonsillitis; otitis, including otitis media; arthritis (psoriatic arthritis); synovitis; men
  • the improvement of intestinal health may be a help in intestinal beneficial growth and suppression of harmful bacteria, help in intestinal health by regulating immunity, or help in smooth bowel movements.
  • antibacterial agent refers to (i) inhibiting, reducing or preventing the growth of bacteria; (ii) inhibit or reduce the ability of the bacteria to cause infection in a subject; or (iii) a substance capable of inhibiting or reducing the ability of a bacterium to multiply or maintain infectivity in the environment.
  • the bacterial infection may include an infection caused by gram-positive bacteria or gram-negative bacteria.
  • the bacterial infection is Clostridium , Helicobactor , Escherichia , Salmonella , Staphylococcus , Streptococcus , Haemophilus ), Klebsiella , Moraxella , Enterobacter , Proteus , Serratia , Pseudomonas , Acinetobacter , Citrobacter ), Stenotrophomonas , Bacteroides , Prevotella , Fusobacterium ( Fusobacterium ) It may include an infection caused by bacteria belonging to the genus. More specifically, the bacterial infection is Clostridium difficile infection (CDI), or Clostridium difficile associated disease (CDAD), for example, Clostridium difficile associated diarrhea. diarrhea) may be included.
  • CDI Clostridium difficile infection
  • CDAD Clostridium difficile associated disease
  • the composition comprises 0.00001 wt% to 80 wt%, for example, 0.00001 wt% to 60 wt%, 0.00001 wt% to 40 wt%, 0.00001 wt% to 30 wt%, 0.00001 wt% to 20 wt% with respect to the total weight of the composition %, 0.00001% to 10% by weight, 0.00001% to 5% by weight, 0.05% to 60% by weight, 0.05% to 40% by weight, 0.05% to 30% by weight, 0.05% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, 0.1% by weight % to 10% by weight, or 0.1% to 5% by weight of the strain, a lysate thereof, a culture medium, or an extract of the culture medium thereof.
  • the term, "included as an active ingredient” means that the strain of the present specification, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or the extract of the culture medium is added to the extent that it can exhibit the above-mentioned effects,
  • the term, “included as an active ingredient” means that the strain of the present specification, the endoplasmic reticulum derived from the strain, the lysate of the strain, the culture medium, or the extract of the culture medium is added to the extent that it can exhibit the above-mentioned effects.
  • drug delivery and stabilization it is meant to include formulations in various forms by adding various components as sub-components.
  • the composition may be a pharmaceutical composition.
  • the pharmaceutical composition may further include a pharmaceutically acceptable diluent or carrier.
  • the diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof.
  • the carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof.
  • the excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof.
  • the disintegrant may be carboxymethyl cellulose calcium, sodium starch glycolate, anhydrous calcium monohydrogen phosphate, or a combination thereof.
  • the binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof.
  • the lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
  • the pharmaceutical composition may be formulated as an oral or parenteral dosage form.
  • Oral dosage forms may be granules, powders, solutions, tablets, capsules, dry syrups, or a combination thereof.
  • the parenteral dosage form may be an injection.
  • the composition may be a health functional food composition.
  • the health functional food composition may be used alone or in combination with other foods or food ingredients of the strain or its culture, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prophylactic, health or therapeutic treatment).
  • the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw material.
  • the beverage composition may contain various flavoring agents or natural carbohydrates as an additional component like a conventional beverage.
  • the natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • sweetener natural sweeteners such as taumartin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used.
  • the health food composition can also be added to nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonated beverages carbonation agent used, or a combination thereof.
  • the health functional food composition may also contain natural fruit juice, fruit juice beverage, fruit flesh for the production of vegetable beverage, or a combination thereof.
  • the composition may be a cosmetic composition.
  • the cosmetic composition may have a cosmetic formulation of, for example, a softening lotion, a nourishing lotion, a massage cream, a nourishing cream, an essence, a pack, a gel, an ampoule, or a skin adhesion type.
  • Components included in the cosmetic composition may include components commonly used in cosmetic compositions in addition to the composition as an active ingredient, for example, conventional adjuvants and carriers such as stabilizers, solubilizers, vitamins, pigments and fragrances. may include
  • composition may be a composition for external application to the skin.
  • the external preparation for skin may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermally delivered patch, drug-containing bandage, lotion, or a combination thereof.
  • the external preparation for skin is a component usually used in external preparations for skin such as cosmetics or pharmaceuticals, for example, an aqueous component, an oily component, a powder component, alcohol, a moisturizer, a thickener, an ultraviolet absorber, a whitening agent, a preservative, an antioxidant, a surfactant, a fragrance , colorant, various skin nutrients, or a combination thereof may be appropriately formulated as needed.
  • the external preparation for skin includes metal-blocking agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belapamil, licorice extract, glablidine, and kaline.
  • metal-blocking agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belapamil, licorice extract, glablidine, and kaline.
  • Fruit hot water extracts, various herbal medicines, tocopherol acetate, glitylittic acid, tranexamic acid and derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, Sugars, such as trehalose, etc. can be mix
  • Another aspect also provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering to the subject in need thereof an effective amount of the composition described above.
  • the subject's condition may be a condition associated with inflammation or a condition associated with a bacterial infection.
  • Administration may be administered by methods known in the art. Administration may be administered directly to a subject by any means, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. can The administration may be systemically or locally.
  • the subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat.
  • the subject may be a subject in need of improvement of a condition associated with inflammation or a condition associated with bacterial infection.
  • the administration is 0.00001 mg to 1,000 mg per subject per day, for example, 0.00001 mg to 500 mg, 0.00001 mg to 100 mg, 0.00001 mg to 50 mg, 0.00001 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg may be administered.
  • the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity, and those skilled in the art
  • the dosage may be appropriately adjusted in consideration of these factors.
  • the number of administration may be once a day or twice or more within the range of clinically acceptable side effects, and may be administered to one or two or more places for the site of administration, and total daily or at intervals of 2 to 5 days
  • the number of days of administration may range from 1 to 30 days per treatment. If necessary, the same treatment can be repeated after a titration period.
  • the dose is the same as that of a human per kg, or the above dose is converted, for example, by the volume ratio (for example, average value) of the target animal and the organ (heart, etc.) of the human One dose can be administered.
  • novel strain and its derived endoplasmic reticulum there is an effect that can be usefully used for the prevention, improvement, or treatment of inflammation-related conditions, or bacterial infections.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • Figure 2 is a graph showing the protein expression level of inflammatory cytokines (TNF- ⁇ and IL-6) in the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • FIG. 3 is a graph showing the protein expression level of inflammatory cytokines (CCL2) and anti-inflammatory cytokines (IL-10) in cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: the endoplasmic reticulum of Example 2.
  • CCL2 inflammatory cytokines
  • IL-10 anti-inflammatory cytokines
  • FIG. 4 is a graph showing the culture rate according to the co-culture of the strain and C. difficile according to one embodiment.
  • FIG. 5 is a graph showing the culture rate of C. difficile according to the treatment with C. difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • CdEV Clostridium difficile ER
  • BBH012 ER of Example 1 strain
  • Type strain ER of Lactobacillus sacchari standard strain.
  • CdEV Clostridium difficile ER
  • BBH012 ER of Example 1 strain
  • Type strain ER of Lactobacillus sacchari standard strain.
  • FIG. 9 is a graph showing the reduction activity of the inflammation induced by Clostridium difficile of the endoplasmic reticulum of the strain according to one embodiment and the increase activity of IL-10, an anti-inflammatory cytokine;
  • CdEV Clostridium difficile ER
  • BBH012 ER of Example 1 strain
  • Type strain ER of Lactobacillus sacchari standard strain.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • FIG. 11 is a graph showing the protein expression level of inflammatory cytokines (TNF- ⁇ and IL-6) in the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • FIG. 12 is a graph showing the protein expression levels of inflammatory cytokines (CCL2) and anti-inflammatory cytokines (IL-10) in cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • CCL2 inflammatory cytokines
  • IL-10 anti-inflammatory cytokines
  • 13 is a graph showing the culture rate according to the co-culture of the strain and C. difficile according to an embodiment.
  • FIG. 14 is a graph showing the culture rate of C. difficile according to the treatment with C. difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • CdEV Clostridium difficile ER
  • BBH007 ER of Example 1 strain
  • Type strain ER of Lactobacillus reuteri standard strain.
  • CdEV Clostridium difficile ER
  • BBH007 ER of Example 1 strain
  • Type strain ER of Lactobacillus reuteri standard strain.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • IL-10 anti-inflammatory cytokine
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • 21 is a graph showing the culture rate of C. difficile according to the treatment with C. difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • CdEV Clostridium difficile ER
  • BBH008 ER of Example 1 strain
  • Type strain ER of standard strain Lactobacillus gasseri.
  • CdEV Clostridium difficile ER
  • BBH008 ER of Example 1 strain
  • Type strain ER of standard strain Lactobacillus gasseri.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • Figure 26 is a graph showing the protein expression level of inflammatory cytokines (TNF and IL-6) in the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • FIG. 27 is a graph showing the protein expression levels of inflammatory cytokines (CCL2) and anti-inflammatory cytokines (IL-10) in cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • CCL2 inflammatory cytokines
  • IL-10 anti-inflammatory cytokines
  • FIG. 28 is a graph showing the culture rate of C. difficile according to the treatment with C. difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH010 endoplasmic reticulum of Example 1 strain
  • Type strain endoplasmic reticulum of Bifidobacillus adolecentis standard strain.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH010 endoplasmic reticulum of Example 1 strain
  • Type strain endoplasmic reticulum of Bifidobacillus adolecentis standard strain.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • 35 is a graph showing the culture rate of C. difficile according to the treatment with C. difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • CdEV Clostridium difficile ER
  • BBH013 ER of Example 1 strain
  • Type strain ER of Lactobacillus paragaseri standard strain.
  • CdEV Clostridium difficile ER
  • BBH013 ER of Example 1 strain
  • Type strain ER of Lactobacillus paragaseri standard strain.
  • Figure 39 is a graph showing the amount of nitric oxide production according to the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • FIG. 40 is a graph showing the protein expression level of inflammatory cytokines (TNF and IL-6) in the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • FIG. 41 is a graph showing the protein expression levels of inflammatory cytokines (CCL2) and anti-inflammatory cytokines (IL-10) in the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • CCL2 inflammatory cytokines
  • IL-10 anti-inflammatory cytokines
  • FIG. 42 is a graph showing the culture rate of C. difficile according to the treatment with C. difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH014 endoplasmic reticulum of Example 1 strain
  • Type strain endoplasmic reticulum of Luminococcus phaesis standard strain.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH014 endoplasmic reticulum of Example 1 strain
  • Type strain endoplasmic reticulum of Luminococcus phaesis standard strain.
  • Fecal Microbiota Transplantation was performed as follows to isolate and identify strains from the composition.
  • PCR amplification was performed on the cultured colonies, and the nucleotide sequence of the 16S rRNA region determined among the isolated and cultured microbial colonies was transferred to another registered BLAST program provided on the website of the National Center for Biotechnology Information (NCBI). The strains were compared and analyzed. As a result of comparative analysis, Lactobacillus sakei BBH 012 having 99% homology was isolated. The selected Lactobacillus sakei BBH 012 strain was deposited with the Korea Center for Biological Resources on December 08, 2020 and was given accession number KCTC 14400BP, and the Lactobacillus sakei BBH 012 strain has the 16S rRNA sequence of SEQ ID NO: 1 (complementary DNA).
  • TSA medium Teryptic soy agar, Green Tech
  • GAM medium Gifu Anaerobic medium containing 5% sheep blood, spread on a plate, and cultured at 37°C for 2 days. Bacteria were selected by this process. PCR amplification was performed on the cultured colonies, and the nucleotide sequence of the 16S rRNA region determined among the isolated and cultured microbial colonies was transferred to another registered BLAST program provided on the website of the National Center for Biotechnology Information (NCBI). The strains were compared and analyzed. As a result of comparative analysis, Lactobacillus reuteri BBH 007 having 99% homology was isolated.
  • NBI National Center for Biotechnology Information
  • the selected Lactobacillus reuteri BBH 007 strain was deposited with the Korea Biological Resources Center on September 3, 2020 and was given an accession number KCTC 14299BP, and the Lactobacillus reuteri BBH 007 strain has a 16S rRNA sequence of SEQ ID NO: 2 (complementary DNA).
  • Lactobacillus gasseri BBH 008 having 98% homology was isolated.
  • the selected Lactobacillus gasseri BBH 008 strain was deposited with the Korea Biological Resources Center on September 3, 2020 and was given an accession number KCTC 14298BP, and the Lactobacillus gasseri BBH 008 strain has a 16S rRNA sequence of SEQ ID NO: 3 (complementary DNA).
  • SEQ ID NO: 3 complementary DNA
  • the selected Bifidobacterium adolescentis BBH 010 strain was deposited with the Korea Biological Resources Center on November 5, 2020 and was given an accession number KCTC 14358BP, and the Bifidobacterium adolescentis BBH 010 strain has a 16S rRNA sequence of SEQ ID NO: 4 (complementary DNA).
  • Lactobacillus paragasseri BBH 013 having 98% homology was isolated.
  • the selected Lactobacillus paragasseri BBH 013 strain was deposited with the Korea Biological Resources Center on December 10, 2020 and was given an accession number KCTC 14405BP, and the Lactobacillus paragasseri BBH 013 strain has a 16S rRNA sequence of SEQ ID NO: 5 (complementary DNA).
  • Ruminococcus faecis BBH 014 having 98% homology was isolated.
  • the selected Ruminococcus faecis BBH 014 strain was deposited with the Korea Center for Biological Resources on December 22, 2020 and was given accession number KCTC 14415BP, and the Ruminococcus faecis BBH 014 strain has the 16S rRNA sequence of SEQ ID NO: 6 (complementary DNA).
  • the endoplasmic reticulum of the strain isolated in the above example was isolated.
  • the isolated strain is cultured in BHIs broth (Brain Heart Infusion-supplemented, Eco cell) or MRS broth (De Man, Rogosa, Sharpe) at 30° C. to 37° C., anaerobic conditions for 3 days. did. Thereafter, the culture medium was centrifuged at 3000 RPM for 20 minutes and then centrifuged again at 3000 RPM for 40 minutes to remove bacterial debris.
  • BHIs broth Brain Heart Infusion-supplemented, Eco cell
  • MRS broth De Man, Rogosa, Sharpe
  • Mouse macrophage Raw264.7 cells were treated with RPMI1640 culture medium containing 20% fetal bovine serum (FBS) and 1% antibiotics (100 U/mL penicillin and 100 ⁇ g/mL streptomycin) in the presence of 5% CO 2 37 Incubated at °C. Thereafter, the Raw 264.7 cells were aliquoted at a concentration of 5 ⁇ 10 4 cells/well in a 48-well plate by 250 ⁇ L, and incubated at 37° C. and 24 hours in a CO 2 incubator.
  • FBS fetal bovine serum
  • antibiotics 100 U/mL penicillin and 100 ⁇ g/mL streptomycin
  • the well supernatant was discarded and a medium supplemented with lipopolysaccharide (LPS) 10ug/ml was dispensed to induce inflammation, followed by further incubation for 4 hours.
  • the supernatant containing LPS was discarded, and the endoplasmic reticulum was added to the medium at a concentration of 0.01 to 100 ug/ml and treated, and then incubated at 37° C. for 16 hours. Thereafter, 50 ⁇ L of the well supernatant and 50 ⁇ L of Griess reagent were mixed and reacted at room temperature for 10 minutes, and then absorbance was measured at 570 nm with a plate reader to measure the amount of nitric oxide produced. , are shown in FIGS. 18, 25, 32 and 39 .
  • 1, 10, 18, 25, 32 and 39 are graphs showing the production amount of nitric oxide according to the cell treatment of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • the endoplasmic reticulum of the strain according to one embodiment further reduced the amount of NO production of the cells induced by inflammation than the level of the negative control.
  • the inflammatory cytokine inhibitory activity of the endoplasmic reticulum of the strain was measured. Specifically, the endoplasmic reticulum was treated at a concentration of 0.01 to 100 ug/ml in LPS-treated Raw264.7 cells in the same manner as above, and then cultured at 37° C. for 48 hours. Then, the protein expression of TNF- ⁇ , IL-6, CCL2 and IL-10 of the cells was measured for absorbance at 540 nm using an ELISA kit (eBioscience, USA) according to the manufacturer's instructions, and the results are shown in each figure. 2, 11, 19, 26, 33 and 40, and 3, 12, 20, 27, 34 and 41 are shown for each strain.
  • 2, 11, 19, 26, 33 and 40 are graphs showing the protein expression level of inflammatory cytokines (TNF- ⁇ and IL-6) in the cell treatment of the endoplasmic reticulum of the strain according to one embodiment ; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • N negative control
  • P untreated control
  • EV endoplasmic reticulum of Example 2.
  • 3, 12, 20, 27, 34 and 41 are proteins of inflammatory cytokines (CCL2) and/or anti-inflammatory cytokines (IL-10) in cell treatment of the endoplasmic reticulum of the strain according to one embodiment It is a graph showing the expression level; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • CCL2 inflammatory cytokines
  • IL-10 anti-inflammatory cytokines
  • the endoplasmic reticulum of the strain significantly reduced inflammatory cytokines compared to the untreated control group, and significantly increased the anti-inflammatory cytokines compared to the untreated control group.
  • strain according to one embodiment can be usefully used for prevention, improvement, or treatment of inflammatory diseases, particularly inflammatory bowel disease or irritable bowel syndrome.
  • Example 1 The antibacterial activity of the strain isolated in Example 1. was analyzed.
  • the strain of Example 1 and C.difficile in 5ml BHI broth (Brain Heart Infusion, Eco cell) It was pre-cultured and adjusted to OD (600 nm) 0.5 using a spectrophotometer. After that, the strain culture medium was inoculated in 30ml BHI broth at a rate of 10% and then cultured anaerobically at 37°C for 48 hours. The cultured strain was centrifuged at 4000RPM for 30 minutes to separate the pellet and the supernatant, and then the pellet was washed 3 times with PBS and then resuspended.
  • C. difficile and the strain of the above example were inoculated into BHI broth at the same ratio in the same amount, and then co-cultured in BHI broth medium under anaerobic conditions for 2 days. Thereafter, the culture rate of C. difficile was measured by the method of colony forming unit calculation, and the results are shown in FIGS. 4 and 13 .
  • the culture supernatant of the strain was centrifuged at 4000 for 30 minutes to separate the endoplasmic reticulum.
  • the separated supernatant was concentrated using centrifuge tubes (Amicon centrifuge tubes), and inoculated to 3 X 10 6 cfu/ml C. difficile at a ratio of 90%, anaerobic conditions for 1 day in BHI broth medium cultured in Thereafter, the culture rate of C. difficile was measured by the method of colony forming unit calculation, and the results are shown in FIGS. 5, 14, 21, 28, 35 and 42 .
  • 4 and 13 are graphs showing the culture rate according to the co-culture of the strain and C. difficile according to an embodiment.
  • 5, 14, 21, 28, 35 and 42 are graphs showing the culture rate of C.difficile according to the treatment with C.difficile of the endoplasmic reticulum of the strain according to one embodiment.
  • the strain and its derived endoplasmic reticulum according to one embodiment were found to completely reduce the culture rate of C. difficile .
  • the strain and/or the endoplasmic reticulum derived therefrom according to one embodiment have antibacterial activity against bacteria, for example, Gram-negative bacteria.
  • these results show that the strain and/or the endoplasmic reticulum derived therefrom according to one embodiment are Clostridium difficile infection (CDI), or the prevention, improvement, or treatment of irritable bowel syndrome resulting therefrom.
  • CDI Clostridium difficile infection
  • the PreMix WST-1 Cell Proliferation Assay System was used for the cytotoxicity test of the endoplasmic reticulum of the strain isolated in Example 2.
  • 6, 15, 22, 29, 36 and 43 are graphs showing the cytotoxicity results of the endoplasmic reticulum of the strain according to one embodiment; N: negative control, P: untreated control, EV: endoplasmic reticulum of Example 2.
  • Clostridium difficile endoplasmic reticulum (CdEV) was treated in an amount of 100gu/ml in mouse macrophage Raw264.7 cells in the same manner as in Experimental Example 1, and then cultured at 37°C for 4 hours. Thereafter, the standard strain of Lactobacillus sacei (ATCC15521), the standard strain of Lactobacillus reuteri (ATCC23272), the standard strain of Lactobacillus gasseri (ATCC33323), the standard strain of Bifidobacillus adolecentis (ATCC15703), Lactobacillus para After treating the standard strain of Gasseri (ATCC4963) or the standard strain of Luminococcus faecis (JCM15917) and the endoplasmic reticulum of the strain of Example 1 in an amount of 0.01ug/ml to 10ug/ml, at 37°C 16 Incubated for an hour, the cell viability was measured in the same manner as in Experimental Example 3, and the results
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH012 ER of Example 1 strain
  • Type strain ER of Lactobacillus Sakei standard strain.
  • CdEV Clostridium difficile ER
  • BBH007 ER of Example 1 strain
  • Type strain ER of Lactobacillus reuteri standard strain.
  • CdEV Clostridium difficile ER
  • BBH008 ER of Example 1 strain
  • Type strain ER of Lactobacillus gasseri standard strain.
  • CdEV Clostridium difficile ER
  • BBH010 ER of the Example 1 strain
  • Type strain ER of the standard strain Bifidobacillus adolesentis.
  • CdEV Clostridium difficile ER
  • BBH013 ER of the Example 1 strain
  • Type strain ER of the Lactobacillus paragaseri standard strain.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH014 endoplasmic reticulum of Example 1 strain
  • Type strain endoplasmic reticulum of Luminococcus phaesis standard strain.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH012 ER of Example 1 strain
  • Type strain ER of Lactobacillus Sakei standard strain.
  • FIG. 9 is a graph showing the reduction activity of inflammation induced by Clostridium difficile of the strain according to one embodiment and the increase activity of IL-10, an anti-inflammatory cytokine;
  • CdEV Clostridium difficile endoplasmic reticulum, BBH012: ER of Example 1 strain, Type strain: ER of Lactobacillus Sakei standard strain.
  • CdEV Clostridium difficile ER
  • BBH007 ER of Example 1 strain
  • Type strain ER of Lactobacillus reuteri standard strain.
  • CdEV Clostridium difficile ER
  • BBH008 ER of Example 1 strain
  • Type strain ER of Lactobacillus gasseri standard strain.
  • FIG. 31 is a graph showing the reduction activity of inflammation induced by the endoplasmic reticulum Clostridium difficile of the strain according to one embodiment;
  • CdEV Clostridium difficile ER
  • BBH010 ER of the Example 1 strain
  • Type strain ER of the standard strain Bifidobacillus adolesentis.
  • CdEV Clostridium difficile ER
  • BBH013 ER of Example 1 strain
  • Type strain ER of Lactobacillus paragaseri standard strain.
  • CdEV Clostridium difficile endoplasmic reticulum
  • BBH014 endoplasmic reticulum of Example 1 strain
  • Type strain endoplasmic reticulum of Luminococcus phaesis standard strain.
  • cytotoxicity was not confirmed in both the endoplasmic reticulum of the strain and the standard strain according to one embodiment.
  • the endoplasmic reticulum of the strain contains pro-inflammatory cytokines TNF, IL-6 and CCL2 compared to the standard strain
  • strain and/or endoplasmic reticulum derived therefrom has significant anti-inflammatory activity, Clostridium difficile infection (CDI), or prevention of irritable bowel syndrome resulting therefrom, improvement, or It means that it can be usefully used for treatment.
  • CDI Clostridium difficile infection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau microorganisme, un lysat de celui-ci, un milieu de culture, un extrait du milieu de culture, des vésicules et des utilisations anti-inflammatoires et/ou antibactériennes associées. Une nouvelle souche et des vésicules dérivées de celle-ci, selon un aspect, peuvent être efficacement utilisées dans la prévention, l'amélioration ou le traitement d'états liés à une inflammation ou une infection bactérienne.
PCT/KR2021/020338 2020-12-31 2021-12-31 Souche de lactobacillus sp., souche de bifidobacterium sp. ou souche de ruminococcus sp., vésicules dérivées de celles-ci et utilisations anti-inflammatoires et antibactériennes associées WO2022146096A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
KR1020200189815A KR102269961B1 (ko) 2020-12-31 2020-12-31 락토바실러스 사케이 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR10-2020-0189818 2020-12-31
KR1020200189821A KR102269965B1 (ko) 2020-12-31 2020-12-31 락토바실러스 파라가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR1020200189818A KR102296288B1 (ko) 2020-12-31 2020-12-31 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR10-2020-0189821 2020-12-31
KR10-2020-0189819 2020-12-31
KR1020200189819A KR102296289B1 (ko) 2020-12-31 2020-12-31 락토바실러스 가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR10-2020-0189820 2020-12-31
KR1020200189820A KR102296290B1 (ko) 2020-12-31 2020-12-31 비피도박테리움 아돌레센티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR10-2020-0189815 2020-12-31
KR10-2021-0004194 2021-01-12
KR1020210004194A KR102269966B1 (ko) 2021-01-12 2021-01-12 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도

Publications (1)

Publication Number Publication Date
WO2022146096A1 true WO2022146096A1 (fr) 2022-07-07

Family

ID=82259536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/020338 WO2022146096A1 (fr) 2020-12-31 2021-12-31 Souche de lactobacillus sp., souche de bifidobacterium sp. ou souche de ruminococcus sp., vésicules dérivées de celles-ci et utilisations anti-inflammatoires et antibactériennes associées

Country Status (1)

Country Link
WO (1) WO2022146096A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115361A1 (fr) * 2016-12-21 2018-06-28 Agriculture And Food Development Authority (Teagasc) Souches humaines de lactobacilli
US20200129571A1 (en) * 2017-06-28 2020-04-30 Moviscom S.r.l. New strain of lactobacillus reuteri with probiotic characteristics, its use and compositions containing said strain
KR102269966B1 (ko) * 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269961B1 (ko) * 2020-12-31 2021-06-28 주식회사 바이오뱅크힐링 락토바실러스 사케이 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269965B1 (ko) * 2020-12-31 2021-06-28 주식회사 바이오뱅크힐링 락토바실러스 파라가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296289B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296288B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296290B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 비피도박테리움 아돌레센티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115361A1 (fr) * 2016-12-21 2018-06-28 Agriculture And Food Development Authority (Teagasc) Souches humaines de lactobacilli
US20200129571A1 (en) * 2017-06-28 2020-04-30 Moviscom S.r.l. New strain of lactobacillus reuteri with probiotic characteristics, its use and compositions containing said strain
KR102269961B1 (ko) * 2020-12-31 2021-06-28 주식회사 바이오뱅크힐링 락토바실러스 사케이 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269965B1 (ko) * 2020-12-31 2021-06-28 주식회사 바이오뱅크힐링 락토바실러스 파라가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296289B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296288B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296290B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 비피도박테리움 아돌레센티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269966B1 (ko) * 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PANPETCH WIMONRAT, SOMBOONNA NARAPORN, PALASUK MATANEE, HIENGRACH PRATSANEE, FINKELMAN MALCOLM, TUMWASORN SOMYING, LEELAHAVANICHKU: "Oral Candida administration in a Clostridium difficile mouse model worsens disease severity but is attenuated by Bifidobacterium", PLOS ONE, vol. 14, no. 1, e0210798, 15 January 2019 (2019-01-15), pages 1 - 18, XP055948385, DOI: 10.1371/journal.pone.0210798 *

Similar Documents

Publication Publication Date Title
KR102269961B1 (ko) 락토바실러스 사케이 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269966B1 (ko) 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269962B1 (ko) 유박테리움 리모숨 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296286B1 (ko) 락토바실러스 람노서스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2020204260A1 (fr) Nouvelle souche de bifidobacterium longum ou composition cosmétique la comprenant
WO2011010770A1 (fr) Nouvelle souche de lactobacillus plantarum et composition la contenant
WO2020040407A1 (fr) Nouvelle souche de cutibacterium avidum, et composition pour prévenir ou traiter la dermatite atopique, comprenant une souche ou un produit cultivé associé
WO2012060579A2 (fr) Biomasse morte de lactobacillus pour une utilisation antimicrobienne, et son procédé de production
WO2019088379A1 (fr) Nouvelles bactéries lactiques et leur utilisation
KR102296288B1 (ko) 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
KR102351147B1 (ko) 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2014069874A1 (fr) Composition permettant d'éliminer des substances kératiniques de la peau comprenant des lactobacillus de thé vert
KR102331483B1 (ko) 류코노스톡 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
EP3592374A1 (fr) Souche de bacillus amyloliquefaciens gf423, et composition ayant des activités anti-oxydantes et anti-inflammatoires ou de prévention ou de traitement de l'hyperlipidémie, y compris un polypeptide produit par celle-ci
KR102351145B1 (ko) 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296287B1 (ko) 락토바실러스 퍼멘텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014054A1 (fr) Souches blautia sp., leuconostoc sp. ou ruminococcus sp. et réticulum endoplasmique dérivé de celles-ci, et leurs utilisations anti-inflammatoires et antibactériennes
KR102269963B1 (ko) 코프로코커스 코메스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102271909B1 (ko) 비피도박테리움 아니말리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102296285B1 (ko) 비피도박테리움 속 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269965B1 (ko) 락토바실러스 파라가세리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2021071159A1 (fr) Composition antidiabétique, hypotenseuse ou antioxydante comprenant un fermentat de levure de rhynchosia nulubilis et son procédé de préparation
WO2021242057A1 (fr) Souche de lactobacillus sp., reticulum endoplasmique dérivé de cette dernière, et utilisation anti-inflammatoire et antibactérienne associée
WO2021242056A1 (fr) Souche de l'espèce bifidobacterium et vésicule extracellulaire dérivée de cette dernière, et leurs utilisations anti-inflammatoires et antibactériennes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21915893

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21915893

Country of ref document: EP

Kind code of ref document: A1